Outset Medical (NASDAQ:OM) Stock: Insider Leslie Trigg Sells 3,403 Shares

Outset Medical logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • CEO Leslie Trigg sold 3,403 shares for $12,489, with the sale made to cover tax withholding on vested equity awards. She retained 191,194 shares afterward.
  • Outset Medical reported quarterly revenue of $33.6 million and EPS of -$0.68, slightly beating analyst estimates for both measures.
  • Analysts’ average rating is Hold, with a $10 average price target; shares traded at $3.16 in the report.
  • MarketBeat previews top five stocks to own in December.

Outset Medical, Inc. (NASDAQ:OM - Get Free Report) CEO Leslie Trigg sold 3,403 shares of the business's stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $3.67, for a total transaction of $12,489.01. Following the completion of the transaction, the chief executive officer directly owned 191,194 shares of the company's stock, valued at approximately $701,681.98. This represents a 1.75% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Outset Medical Price Performance

Shares of NASDAQ:OM traded down $0.23 during trading on Tuesday, reaching $3.16. The company had a trading volume of 142,514 shares, compared to its average volume of 107,148. The company has a fifty day moving average of $3.75 and a two-hundred day moving average of $4.09. The company has a current ratio of 4.86, a quick ratio of 3.85 and a debt-to-equity ratio of 1.19. The stock has a market capitalization of $59.63 million, a P/E ratio of -0.82 and a beta of 1.93. Outset Medical, Inc. has a 12 month low of $2.84 and a 12 month high of $6.49.

Outset Medical (NASDAQ:OM - Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.69) by $0.01. Outset Medical had a negative net margin of 58.33% and a negative return on equity of 66.98%. The company had revenue of $33.60 million during the quarter, compared to the consensus estimate of $31.40 million. Equities research analysts forecast that Outset Medical, Inc. will post -3.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on OM. Weiss Ratings lowered Outset Medical from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Friday, August 21st. Wall Street Zen upgraded Outset Medical from a "sell" rating to a "hold" rating in a report on Saturday, August 15th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Outset Medical has an average rating of "Hold" and an average target price of $10.00.

Get Our Latest Report on Outset Medical

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in OM. Marshall Wace LLP raised its position in Outset Medical by 128.0% in the 3rd quarter. Marshall Wace LLP now owns 483,380 shares of the company's stock worth $1,450,000 after purchasing an additional 271,387 shares during the period. Empowered Funds LLC purchased a new stake in Outset Medical during the third quarter valued at about $74,000. Squarepoint Ops LLC purchased a new stake in Outset Medical during the second quarter valued at about $98,000. Bank of New York Mellon Corp purchased a new stake in Outset Medical during the second quarter valued at about $121,000. Finally, Marquette Asset Management LLC bought a new position in shares of Outset Medical during the second quarter valued at about $212,000.

Outset Medical Company Profile

(Get Free Report)

Outset Medical is a medical technology company that develops and sells products for hemodialysis, a treatment that filters waste and excess fluid from the blood. Its main product is the Tablo Hemodialysis System, an integrated dialysis platform designed for use in hospitals, clinics and home settings. Tablo combines dialysis equipment with water purification and a touchscreen interface, aiming to simplify treatment setup and operation. The system also supports access to treatment data through connected software tools.

See Also

Insider Buying and Selling by Quarter for Outset Medical (NASDAQ:OM)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Outset Medical Right Now?

Before you consider Outset Medical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Outset Medical wasn't on the list.

While Outset Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines